Medical News

RSS

HHS and PEPFAR approve the 100th HIV/AIDS antiretroviral drug

The U.S. Department of Health and Human Services (HHS) today marked today marked the recent approval of the 100th antiretroviral drug in association with the President's Emergency Plan for AIDS Relief (PEPFAR), aimed at the prevention, treatment, and care of people infected with and affected by HIV/AIDS worldwide.

7 Oct 2009

Hydrogen Advertising partners with National MS Society to create new programs for MS affected people

Hydrogen Advertising has partnered with the Greater Washington Chapter of the National MS Society to handle creative duties for the organization on a pro bono basis. The agency will build upon the success of the National MS Society’s recent “Why Here?” campaign, helping further regional awareness and understanding of this debilitating disease.

7 Oct 2009

U.S children exposed to more violence and abuse than has been previously recognized, says study

A new study from the University of New Hampshire finds that U.S. children are routinely exposed to even more violence and abuse than has been previously recognized, with nearly half experiencing a physical assault in the study year.

7 Oct 2009

EmEx recognizes Aurora BayCare Medical Center in Wisconsin as Emergency Center of Excellence

Aurora BayCare Medical Center in Green Bay, Wisconsin, is the first U.S. hospital to be verified as an Emergency Center of Excellence(TM) by Emergency Excellence (EmEx), a company specializing in emergency department benchmarking. At the annual meeting of the Emergency Nurses Association in Baltimore, Emergency Excellence recognized Aurora BayCare Medical Center's dedication to excellent emergency care.

7 Oct 2009

Autism rates among U.S. children is one in 91, says new report

A new report out yesterday places autism rates among U.S. children at one in 91, with autism now affecting one in 58 boys. These new numbers, from Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services, are prompting outrage from parents and autism advocates over inaction from government health agencies in addressing the crisis affecting hundreds of thousands of American families.

7 Oct 2009

US Spine introduces Phantom Plus Interbody Fusion System

US Spine® is pleased to announce the launch of the Phantom Plus™ Interbody Fusion System. Phantom Plus provides spine surgeons with next generation instrumentation and implants that offer a compliment to US Spine’s posterior fixation systems. Features include tapered leading edges for easy insertion, a higher degree of doming to more closely match endplate anatomy, anti-migration teeth, and advanced instrumentation for multiple insertion techniques.

7 Oct 2009

Real-time tracking of patients and providers to improve hospital care

On any day at three of Massachusetts General Hospital’s outpatient clinics, up to 100 patients may be seen for routine, sick or urgent care. When they register, patients 18 and older are asked to wear a wrist coil with an active-RFID tag. Compliance is virtually 100 percent once patients understand the purpose: to help care providers find ways to spend more time providing better care.

7 Oct 2009

FDA provides Genzyme a complete response letter for Clolar NDA

Genzyme Corporation announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled clinical study be conducted for label expansion of Clolar in this indication.

7 Oct 2009

FDA completes inspection of Catalent Pharma's manufacturing facility in Germany

Catalent Pharma Solutions announces that its integrated dose form development, manufacturing and packaging facility in Schorndorf, Germany, has successfully completed an FDA inspection.

7 Oct 2009

Daily doses of imatinib mesylate double survival rates in Ph+ ALL affected children

Results of a phase two clinical trial published October 5th in the Journal of Clinical Oncology show that adding continuous daily doses of a targeted drug called imatinib mesylate to regular chemotherapy more than doubled three-year survival rates for children with a high risk type of blood cancer called Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

7 Oct 2009

Humana announces expansion of its Medicare offerings in California

Humana Inc. announced today an expansion of its Medicare offerings in California. Beginning on November 15, individuals eligible for Medicare in Fresno, San Bernardino and Riverside counties can enroll in a local Humana Gold Plus HMO plan – for a January 1, 2010 effective date.

7 Oct 2009

Winner Medical receives approval to list its common stock on NYSE Amex

Winner Medical Group Inc. (OTC Bulletin Board: WWIN; "Winner Medical", or the "Company"), a leading manufacturer and the largest exporter by volume in the medical dressing industry in China, today announced that the Company received approval to list its common stock on NYSE Amex.

7 Oct 2009

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

More studies that directly compare the effectiveness of different biologic drugs for rheumatoid arthritis (RA) are needed, say Cochrane Researchers. The researchers reviewed all previous Cochrane Systematic Reviews assessing the effectiveness of biologic disease-modifying drugs for treatment of RA and found that although all were very effective, there was little data on direct comparisons between the drugs that could help doctors decide which to prescribe.

7 Oct 2009

HSCI declares preliminary price range for its initial public offering

Joint Stock Company Human Stem Cell Institute” (“HSCI” or “the Company”), Russia’s leader in stem cell technology, today announced the preliminary price range for its initial public offering (“IPO”).

7 Oct 2009

Research on malarial drugs for travelers

A new review of existing research finds that a combination drug and the common antibiotic doxycycline allow travelers to fend off malaria with the fewest side effects in areas where the parasite is resistant to a widely accepted preventive treatment.

7 Oct 2009

Presbyterian Hospital implements Defensive Monitoring solution for their post-surgical patients

Presbyterian Hospital will “go live” today with a Defensive Monitoring™ solution for their post-surgical patients: A Prefense™ Early Detection and Notification™ System from Nihon Kohden America, Inc.

7 Oct 2009

White House hosts white-coated doctors for health reform pitch

President Obama spoke to a group of doctors in the Rose Garden Monday, the Associated Press reports. "[N]obody has more credibility with the American people on this issue than you do," he said (Babington, 10/5).

7 Oct 2009

Pregis closes debt private placement and credit facility amendment

Pregis Corporation, a leading international manufacturer, marketer, and supplier of protective packaging products and specialty packaging solutions, today announced that it has closed on the offering of euro 125,000,000 aggregate principal amount of additional second priority senior secured floating rate notes due 2013.

7 Oct 2009

Imagexpres inks distributor/supply agreement with Dalton Corporation

ImageXpres Corporation, today announced it has signed a Distributor/Supply Agreement with Dalton Corporation, a Taiwan-based manufacturer of digital hardware and software products, that are sold throughout the world, including private label for well-known brands.

7 Oct 2009